Application of eptifibatide injection in acute ischemic cerebrovascular disease

Abstract

Objective To evaluate the treatment effectiveness and safety of eptifibatide injection in the treatment of acute ischemic cerebrovascular disease （ICVD）. Methods Clinical data of 34 ICVD patients treated with eptifibatide injection were retrospectively analyzed. The indexes of blood rheology, blood coagulation and blood lipid before and after treatment were detected. The dose-effect relationship between the cumulative injection dose and each index was established, and the effective cumulative dose was predicted by the normal index values. The effectiveness were verified by comparing National Institute of Health Stroke Scale （NIHSS） and digital subtraction angiography（DSA） score before and after treatment, and the safety were evaluated after treatment. Results The indexes of blood rheology, blood coagulation and blood lipid were improved to different degree before and after treatment, and the differences were statistically significant （all P < 0.05）. The blood rheology index could be simulated as a quadratic equation of one variable, and R2 was greater than 0.95; in the simulation of blood coagulation indexes, the amount of eptifibatide exerted mild effect on thrombin time. Hence, the corresponding equation could not be simulated, and the remaining indexes could be simulated with a quadratic equation with one variable, and all R2 were greater than 0.95. All patients did not develop symptomatic intracranial hemorrhage after administration. The scores of NIHSS were significantly decreased after one week of treatment （P < 0.05）. Conclusion It is safe and effective to strengthen the anti-platelet aggregation therapy with eptifibatide injection in ICVD patients.

Keywords

• |acute ischemic cerebrovascular disease|eptifibatide|platelet|treatment effectiveness|safety